A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study.

Abreu M, Tumyan A, Elhassan A, Peicher K, Papacostea O, Dimachkie P, Siddiqui MS, Pop LM, Gunasekaran U, Meneghini LF, Adams-Huet B, Li X, Lingvay I

Diabetes, obesity & metabolism28 Jun 2019Cited by 9 (Europe PMC)

PMID31144435DOI10.1111/dom.13794PepBankPUB-31144435

Publisher page PubMedAsk about this study

Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and HbA1c of 10% or more, detemir plus liraglutide lowered HbA1c more than detemir plus aspart over 6 months.
In plain wordsIn adults with very high blood sugar, the regimen of detemir plus liraglutide lowered HbA1c more than detemir plus aspart.
Peptide
Liraglutide
Outcome
DecreaseHbA1c change
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Estimated treatment difference
−1.1%
GLP1RA plus basal insulin vs basal-bolus insulin
Source sentences
Summary
HbA1c decreased more with GLP1RA plus basal insulin [12.2% (95% CI 11.8% to 12.6%) to 8.1% (95% CI 7.4% to 8.7%)] compared with basal-bolus insulin [11.8% (95% CI 11.5% to 12.2%) to 8.8% (95% CI 88.1% to 9.55%)]; estimated treatment difference (ETD) of -1.1% (95% CI -2.0% to -0.1%) (non-inferiority…
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443501
02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high HbA1c, detemir plus liraglutide led to a lower body weight than detemir plus aspart.
In plain wordsIn adults with very high blood sugar, the regimen of detemir plus liraglutide led to lower body weight than detemir plus aspart.
Peptide
Liraglutide
Outcome
DecreaseBody weight estimated treatment difference
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Secondary
Outcome group
Body weight · Metabolic and weight
Measurements
Body weight estimated treatment difference
−3.7 kg
GLP1RA plus basal insulin vs basal-bolus insulin
Source sentences
Summary
Compared with basal-bolus insulin, treatment with GLP1RA plus basal insulin led to a body weight ETD of -3.7 kg (95% CI -5.8 to -1.5; P = .001)
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443502
03HumanNot a test of Liraglutide aloneRandomized controlled trialSafety outcome
In adults with type 2 diabetes and high HbA1c, fewer patients had hypoglycaemia with detemir plus liraglutide than with detemir plus aspart.
In plain wordsIn adults with very high blood sugar, fewer people had low blood sugar with detemir plus liraglutide than with detemir plus aspart.
Peptide
Liraglutide
Outcome
DecreasePatients with hypoglycaemia
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Secondary
Outcome group
Adverse events · Metabolic and weight
Source sentences
Summary
fewer patients experiencing hypoglycaemia [66.1% vs 35.2% (P = .002)]
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443503
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high HbA1c, detemir plus liraglutide gave greater improvement in general and current health perception than detemir plus aspart.
In plain wordsIn adults with very high blood sugar, people on detemir plus liraglutide rated their general health better than people on detemir plus aspart.
Peptide
Liraglutide
Outcome
IncreaseGeneral and current health perception
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Secondary
Outcome group
Quality of life · Whole body
Source sentences
Summary
greater improvements in general/current health perception, treatment satisfaction, and fear of hypoglycaemia
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443504
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high HbA1c, detemir plus liraglutide gave greater improvement in treatment satisfaction than detemir plus aspart.
In plain wordsIn adults with very high blood sugar, people on detemir plus liraglutide were more satisfied with treatment than people on detemir plus aspart.
Peptide
Liraglutide
Outcome
IncreaseTreatment satisfaction
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Secondary
Outcome group
Quality of life · Whole body
Source sentences
Summary
greater improvements in general/current health perception, treatment satisfaction, and fear of hypoglycaemia
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443505
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high HbA1c, detemir plus liraglutide gave greater improvement in fear of hypoglycaemia than detemir plus aspart.
In plain wordsIn adults with very high blood sugar, people on detemir plus liraglutide feared low blood sugar less than people on detemir plus aspart.
Peptide
Liraglutide
Outcome
IncreaseFear of hypoglycaemia
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Secondary
Outcome group
Quality of life · Whole body
Source sentences
Summary
greater improvements in general/current health perception, treatment satisfaction, and fear of hypoglycaemia
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443506
07HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes and high HbA1c, patients on detemir plus liraglutide took a lower total daily insulin dose than patients on detemir plus aspart.
In plain wordsIn adults with very high blood sugar, people on detemir plus liraglutide needed less insulin per day than people on detemir plus aspart.
Peptide
Liraglutide
Outcome
DecreaseTotal daily insulin dose
Study
n = 120
Comparator
Detemir plus aspart (basal-bolus insulin)
Analysis
Secondary
Outcome group
Glycemic control · Metabolic and weight
Measurements
Estimated treatment ratio
0.68 ratio
total daily insulin dose
Source sentences
Summary
while taking a lower total daily dose of insulin [estimated treatment ratio 0.68 (95% CI 0.55 to 0.84)]
2 context sentences(design, population, supporting numbers)
Summary · context
The SIMPLE study was a 6-month pragmatic, randomized, open-label trial testing the effectiveness of two approaches to treat patients with type 2 diabetes and HbA1c ≥10%.
Summary · context
We randomized patients to detemir plus liraglutide or detemir plus aspart (before each meal).
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-3114443507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.